How many insider trades does FilingIQ track for ABSI?

FilingIQ tracks 125 Form 4 insider transactions for ABSI (Absci Corp), covering filings from Jul 26, 2021 onwards. 34 of those were filed in the last 90 days.

Are ABSI insiders net buyers or net sellers?

Across the full Form 4 history for ABSI, 19 transactions (15%) were open-market purchases and 4 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ABSI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ABSI in?

Absci Corp (ABSI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $387.21M.

ABSI insider trading

Healthcare

Absci Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

125

Last 90 days

Buys / sells

15% / 3%

Market cap

$387.21M

About Absci Corp

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Company website: www.absci.com

ABSI insider activity at a glance

FilingIQ has scored 125 insider transactions for ABSI since Jul 26, 2021. The most recent filing in our index is dated May 13, 2026.

Across the full history, 19 open-market purchases and 4 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ABSI insider trades is 55.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ABSI trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ABSI?: FilingIQ tracks 125 Form 4 insider transactions for ABSI (Absci Corp), covering filings from Jul 26, 2021 onwards. 34 of those were filed in the last 90 days.
Are ABSI insiders net buyers or net sellers?: Across the full Form 4 history for ABSI, 19 transactions (15%) were open-market purchases and 4 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ABSI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ABSI in?: Absci Corp (ABSI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $387.21M.

Methodology & sources

Every ABSI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.